Etravirine: adverse event reports filed with FDA

1,285

reports as suspect product

0% of all reports · about 66 a year

17

reports, 12 months to June 2026

18 in the 12 months before

91.1%

marked serious by the reporter

79.6% across the class

13.2%

record death among outcomes, as reported

169 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Etravirine reports recording the termmedian drug in human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor

1. Drug resistance14.8%190
2. Virologic failure12.4%159
3. Treatment failurethe treatment did not work12.3%158
4. Viral mutation identified9.7%125
5. Drug interactionan interaction between medicines9.1%117
6. Pathogen resistance7.5%96
7. Deaththe patient died; cause not stated by this term6.5%83
8. Lipodystrophy acquiredchanges in body fat distribution6.3%81
9. CD4 lymphocytes decreased6.1%79
10. CD4/CD8 ratio decreased6%77
11. Mitochondrial toxicity5.2%67
12. Diplopiadouble vision5.1%65
13. Eyelid ptosis5.1%65
14. Foetal exposure during pregnancythe unborn baby was exposed to the medicine4.5%58
15. Progressive external ophthalmoplegia4.3%55
16. Treatment noncompliancethe treatment was not taken as directed3.3%42
17. Drug ineffectivethe medicine did not work as expected3.1%40
18. Exposure during pregnancythe medicine was taken during pregnancy2.8%36
19. Premature babya baby born early2.6%34
20. Rashskin rash2.6%33
21. Anaemialow red blood cells2.3%29
22. Off label useused for a purpose or in a way not on the label2.2%28
23. Ophthalmoplegia2%26
24. Maternal exposure during pregnancythe mother took the medicine during pregnancy1.9%25
25. Gastrointestinal disorder1.8%23
26. Nauseafeeling sick1.8%23
27. Pyrexiafever1.8%23
28. Diarrhoealoose or frequent stools1.7%22
29. Multiple-drug resistance1.7%22
30. Astheniaweakness or lack of energy1.6%21

Top 30 of 343 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 29,070 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 27.5% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 1,285 reports.

Drugs most often listed in the same reports

Other products listed in reports where Etravirine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Etravirine as a suspect or interacting product; reports listing it only as a concomitant medication (573) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.